Navigation Links
Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
Date:5/9/2011

SAN DIEGO, May 9, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter of 2011.  For the three months ended March 31, 2011, Orexigen reported a net loss of $11.6 million, or $0.24 per share, as compared to a net loss of $14.1 million, or $0.30 per share, for the first quarter of 2010.  As of March 31, 2011, Orexigen had $39.6 million in cash and cash equivalents and an additional $36.9 million in marketable securities, for a total of approximately $76.6 million.

"Over the last several months, together with our partner, Takeda, and our external advisors, we have been preparing for a meeting with FDA to discuss a viable path forward for Contrave®," said Michael Narachi, president and CEO of Orexigen. "We have submitted to the Agency a specific, innovative, and robust proposal to assess cardiovascular risk and have confirmed a meeting with the Agency later this quarter to discuss our proposal."

Total operating expenses for the first quarter of 2011 were $13.3 million compared to $14.0 million for the first quarter of 2010. This decrease in operating expenses primarily reflects a decrease in research and development expenses of $1.4 million principally related to the reduction in costs incurred in connection with the preparation for our NDA filing for Contrave in the first quarter of 2011 as compared to same period in 2010. This overall decrease was partially offset by an increase in general and administrative expenses principally related to one-time corporate realignment costs.

Conference Call Today at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) The Orexigen management team will host a teleconference and webcast to discuss the first quarter 2011 financial results and recent business highlights. The l
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
2. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
3. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
4. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
5. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
6. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
7. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
8. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
9. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
10. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
11. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Partnership to Fight Chronic Disease (PFCD) released a public opinion poll ... new study analyzing the impact of increased cost sharing on patient ... to educate policy makers and the public on the costs of ... how the Iowa healthcare exchange could be ...
(Date:1/23/2015)... 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), ... operable and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... take place on January 26 at 10:30 a.m. EST at ...
(Date:1/23/2015)... More than a third of reproductive-aged women enrolled in ... insurance, filled a prescription for an opioid pain medication each ... Morbidity and Mortality Weekly Report (MMWR). Opioids ... to severe pain.  They are also found in some prescription ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... considered Charles Atlases of the pharmaceutical realm have been ... the diseases they once dispatched with ease have developed ... for antibiotics, although not confined to them. Chemotherapy drugs ... a particular cancer now are often rendered near powerless ...
... N.J., Aug. 18 Actavis Group, the,international ... has,received approval from the U.S. Food & ... (XL) 300mg. Distribution,of the product will commence ... available in,300mg strength, are the generic equivalent ...
... Drug,Stores Corporation (NYSE: LDG ) today announced that its ... shares of $0.14 per share,payable on October 10, 2008 to ... 2008., About the Company, Headquartered in Walnut Creek, ... of the most recognized retail drug store,chains on the West ...
... with HIV, the virus manages to escape from the ... dementia and other cognitive disorders. Now, scientists at the ... found strong evidence that a component of the cell ... in the blood of HIV-infected peoplehelps HIV to penetrate ...
... nutrient, researchers say , , MONDAY, Aug. 18 (HealthDay News) -- ... for hip fracture by more than 70 percent, University of ... recommendation that people maintain adequate intake of vitamin D, which ... to sunlight. , The fracture-vitamin D link "has been observed ...
... Anniversary of His Heroism - Morris Animal Foundation ... Dogs Dies of Cancer - Leading Cause of Death in ... claimed a hero police dog,and Morris Animal Foundation (MAF) is ... in Colorado. MAF first honored Rocky six,years ago when his ...
Cached Medicine News:Health News:New method to overcome multiple drug resistant diseases developed by Stanford researchers 2Health News:New method to overcome multiple drug resistant diseases developed by Stanford researchers 3Health News:New method to overcome multiple drug resistant diseases developed by Stanford researchers 4Health News:New method to overcome multiple drug resistant diseases developed by Stanford researchers 5Health News:Actavis Receives Approval of Generic Wellbutrin XL(R) 300mg in the U.S. 2Health News:Chemical liberated by leaky gut may allow HIV to infect the brain, Einstein scientists find 2Health News:Chemical liberated by leaky gut may allow HIV to infect the brain, Einstein scientists find 3Health News:Chemical liberated by leaky gut may allow HIV to infect the brain, Einstein scientists find 4Health News:Low Vitamin D Raises Women's Hip Fracture Risk 2Health News:Hero Police Dog Succumbs to Cancer - Morris Animal Foundation Honors 'Rocky' - Also Honored 'Rocky' Six Years Ago When He Was Shot 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: